Vaccination Uptake, Intent, and Confidence

Overview

This monthly dashboard expands on the weekly COVID-19, flu, and RSV data available. It allows users to take a deeper dive into attitudes and behaviors associated with COVID-19, flu, and RSV vaccine uptake by a comprehensive set of demographic characteristics, behavioral and social drivers of vaccination, and barriers to vaccination.

Methods

Vaccination coverage estimates among adults 18 years and older are based on data from CDC's National Immunization Survey–Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report. Estimates of vaccination coverage on this dashboard may vary from estimates on the weekly dashboard; weekly estimates are derived from compiling interview data from all prior weeks, while monthly estimates are derived only from interviews conducted that month.

Data Summary

COVID-19 and influenza vaccines

• As of November 2024, 18.6% of adults 18+ in the U.S. have received a 2024–25 COVID-19 vaccine and 35.1% have received a 2024–25 flu vaccine.
  • Coverage is highest among adults ≥65 years (37.9% and 58.8%, respectively).
  • Vaccination coverage varied by jurisdiction, ranging from 36.7% (Vermont) to 6.0% (Puerto Rico) for COVID-19 vaccine, and from 51.8% (Vermont) to 21.2% (Utah) for flu vaccine.
• 12.0% and 13.3% reported they definitely will get vaccinated with a 2024–25 COVID-19 vaccine and a 2024–25 influenza vaccine, respectively.
• Concern about disease, confidence in vaccine safety, and confidence in the importance of the vaccine to prevent disease continue to be drivers of vaccination.
  • Nationally, adults who expressed moderate to high concern about getting COVID-19 disease are more likely to have received a 2024–25 COVID-19 vaccine compared with adults who express little to no concern (30.1% vs. 12.0%). Adults who consider the vaccines safe and who consider the vaccines important to protect them are also more likely to have received the 2024–25 COVID-19 vaccine (33.0% vs. 4.7% and 28.8% vs. 1.8%, respectively).
  • Nationally, adults who expressed moderate to high concern about getting flu are more likely to have received a 2024–25 flu vaccine compared with adults who express little to no concern (43.9% vs. 31.9%). Adults who consider the vaccines safe and who consider the vaccines important to protect them are also more likely to have received the 2024–25 vaccine (49.8% vs. 15.2% and 47.9% vs. 6.4%, respectively).
  • According to jurisdiction-level data from September–October 2024 among adults 18+, jurisdictions with higher prevalence of concern about disease, confidence in vaccine safety, confidence that the vaccine is important to protect the recipient from disease, and healthcare provider recommendations tended to have higher COVID-19 and flu vaccination coverage (statistically significant correlations ranging from 0.48-0.77).
• The percent of adults reporting a healthcare provider had recommended vaccination since July 1, 2024, was 22.4% for COVID-19 and 39.5% for flu vaccine.
• Few (6.0%) adults reported it was or would be somewhat or very difficult to get a COVID-19 vaccine.

RSV vaccine

• As of November 2024, RSV vaccination coverage was 36.1% among adults aged ≥75 years and 30.1% among those aged 60–74 years at increased risk of severe RSV disease.
  • Among adults aged ≥75 years, 7.6% reported that they definitely will be vaccinated against RSV, and 17.4% among those aged 60–74 years at increased risk.

• RSV vaccination coverage is highest among White, non-Hispanic adults compared with other races and ethnicities among both adults aged ≥75 years (41.2%) and adults aged 60–74 years at increased risk (32.2%).

• According to jurisdiction-level data from September–October 2024 among adults ≥75 years, jurisdictions with higher prevalence of concern about RSV disease, confidence in vaccine safety, confidence that the vaccine is important to protect the recipient from disease, and healthcare provider recommendations tended to have higher RSV vaccination coverage, with correlations ranging from 0.35 for concern about RSV disease to 0.67 for confidence in RSV vaccine safety.

Download Data